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BACKGROUND: Prostate cancer mortality rates in the United States declined by >40% between 1991 and 2005. The impact of
changes in primary treatment and adjuvant and neoadjuvant hormone therapy on this decline is unknown. METHODS: The authors
applied 3 independently developed models of prostate cancer natural history and disease detection under common assumptions
about treatment patterns, treatment efficacy, and survival in the population. Primary treatment patterns were derived from the Sur-
veillance, Epidemiology, and End Results registry; data on the frequency of hormone therapy were obtained from the CaPSURE (Can-
cer of the Prostate Strategic Urologic Research Endeavor) database; and treatment efficacy was based on estimates from
randomized trials and comparative effectiveness studies of treatment alternatives. The models projected prostate cancer mortality
without prostate-specific antigen screening and in the presence and absence of treatment benefit. The impact of primary treatment
was expressed as a fraction of the difference between observed mortality and projected mortality in the absence of treatment bene-
fit. RESULTS: The 3 models projected that changes in treatment explained 22% to 33% of the mortality decline by 2005. These contri-
butions were accounted for mostly by surgery and radiation therapy, which increased in frequency until the 1990s, whereas hormone
therapies contributed little to the mortality decline by 2005. Assuming that treatment benefit was less for older men, changes in
treatment explained only 16% to 23% of the mortality decline by 2005. CONCLUSIONS: Changes in primary treatment explained a
minority of the observed decline in prostate cancer mortality. The remainder of the decline probably was because of other
interventions, such as prostate-specific antigen screening and advances in the treatment of recurrent and progressive disease. Cancer
2012;118:5955-63. VC 2012 American Cancer Society.
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INTRODUCTION
Since the early 1990s, we have witnessed a spectacular decline in prostate cancer mortality in the United States. Between
1991 and 2005 alone, prostate cancer mortality declined by 42% from 103 to 60 deaths per 100,000 men ages 50 to 84
years. This remarkable success story coincided with dramatic changes in the control of the disease: the widespread adop-
tion of prostate-specific antigen (PSA) screening beginning around 1987, advances in treatment of early stage tumors, and
changes in the detection and treatment of recurrent and progressive disease.
Because of the simultaneous dissemination of PSA screening and changes in treatment, a clear explanation for the
drop in prostate cancer deaths has been elusive. In a 2003 editorial titled The Prostate Cancer Conundrum, Albertsen ques-
tioned the relative roles of primary surgery and adjuvant hormone therapy for localized disease in explaining the mortality
trends.1 Rates of surgery surged in the 1980s after the development of nerve-sparing techniques for radical prostatectomy
(RP). Randomized trial results indicate that RP improves disease-specific survival relative to watchful waiting, with a 38%
reduction in the risk of prostate cancer death.2 Hormone therapy, which previously was reserved for men with advanced
cancers, is particularly efficacious when used in combination with external-beam radiation therapy (RT), and its use
dramatically increased in the middle to late 1990s.3
The role of PSA screening in explaining the drop in disease-specific deaths also has been questioned4 but has not
been conclusively determined. Long-awaited results from 2 large prostate cancer screening trials failed to convincingly
establish screening benefit: The European trial demonstrated a 20% lower disease-specific mortality rate in the screening
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arm over a median of 9 years,5 and the US trial demon-
strated no difference between the control and screening
arms after 7 years of complete follow-up.6 However, it is
generally recognized that, because men on the control
arm of the US trial received ‘‘usual care’’, which included
routine screening,7 the results should be interpreted as a
comparison between moderate and high screening
intensities.8
The Cancer Intervention and SurveillanceModeling
Network (CISNET) prostate group was formed to quan-
tify the relative contributions of screening and treatment
changes to the mortality declines. Previously, CISNET
prostate models were used to demonstrate that early detec-
tion because of screening could account for approximately
45% to 70% of the decline in prostate cancer mortality
under a ‘‘stage-shift’’ mechanism for screening benefit.
The stage-shift mechanism specifies that disease shifted to
an earlier stage by screening enjoys a corresponding
improvement in disease-specific survival. This mechanism
is a central motivator underlying all cancer screening stud-
ies; however, the extent to which it holds is not known
conclusively in the case of prostate cancer.
In this article, we take a different approach and
quantify the fraction of the mortality decline plausibly
caused by treatment changes among men with nonmeta-
static disease. To do this, we model the dissemination and
benefits of first-line treatment (RP and RT alone or in
combination with hormone therapy) and project their
impact on mortality in the absence of screening. The
results are informative about the likely role of treatment
changes in explaining prostate cancer mortality declines.
In addition, they are suggestive of a potential role for
screening and/or other practice changes, such as treatment
for recurrent or progressive cancer.
MATERIALS AND METHODS
The Cancer Intervention and Surveillance
Modeling Network Paradigm
The CISNET approach, at its core, is a model of disease
natural history, representing the individual experience of
disease onset and progression, diagnosis, and death in the
absence of any interventions of interest. Interventions,
such as screening and/or treatment, are then superim-
posed based on analyses of patterns of care in the popula-
tion and on known efficacy from randomized trials or
assumed mechanisms of benefit.
In the current setting, the models first produce pro-
jections of prostate cancer mortality in the absence of
screening and treatment among men diagnosed from
1975, because limited, population-representative data are
available before 1975 to inform the natural history mod-
els. By ‘‘absence of treatment’’ we mean in the absence of
treatment benefit, as all projections under this setting
assume that primary treatment interventions are not bene-
ficial (ie, the hazard ratio for disease-specific survival
equals 1.0 relative to conservative management [CM]).
The models also project mortality in the presence of treat-
ment but in the absence of screening, ie, assuming that
stage and grade distributions at diagnosis would have
remained as observed in the pre-PSA era. We project mor-
tality in the absence of screening because projections in
the presence of screening would rely on an assumed sur-
vival benefit of screening, a benefit with greater uncer-
tainty than the benefits of primary treatments.
The impact of treatment occurs through changes in
treatment distributions (Fig. 1) as well as through treat-
ment benefit (treatment-specific hazard ratios for disease-
specific survival that are less than 1.0 relative to CM). We
use the terms ‘‘in the presence of treatment’’ and ‘‘in the
presence of changes in treatment’’ interchangeably. By
comparing the mortality projections in the presence and
absence of treatment with observed disease-specific mor-
tality trends, we can quantify the fraction of the mortality
decline associated with treatment. For example, if a pro-
jection in the presence of treatment lies half way between
our projection in the absence of treatment and observed
mortality, we would conclude that treatment alone
(because of treatment benefit and changes in treatment
Figure 1. Primary treatment dissemination patterns in the
United States are illustrated. Radical prostatectomy (RP) is
defined by Surveillance, Epidemiology, and End Results
(SEER) codes 50, 58, 60, and 68 before 1997 and by SEER
codes 50 and 70 beginning in 1998. Radiation therapy (RT)
is defined according to SEER categories as beam radiation,
radioactive implants, radioisotopes, a combination of beam
with implants or isotopes, or radiation with method or source
unspecified. Androgen-deprivation therapy (ADT) data are
from CaPSURE (Cancer of the Prostate Strategic Urologic
Research Endeavor). CM indicates conservative management.
Original Article
5956 Cancer December 1, 2012
patterns) accounts for approximately 50% of the observed
mortality decline.
The CISNET prostate working group consists of 3
groups developing independent models of prostate can-
cer natural history informed by common information on
patterns of screening, disease incidence, and other-cause
mortality. Each natural history model is different, but
each model is calibrated using age-specific, year-specific,
stage-specific, and grade-specific prostate cancer inci-
dence from the Surveillance, Epidemiology, and End
Results (SEER) Program before and after the introduc-
tion of PSA screening. The calibrated natural history
models are then combined with common information
on treatment patterns and disease-specific survival to
project prostate cancer mortality under plausible assump-
tions about treatment efficacy.
In the section below, we briefly describe each natural
history model and the calibration methods used. Then,
we detail survival modeling procedures, our data sources,
and assumptions regarding treatment efficacy.
Model Structures
Detailed descriptions of individual models and a joint
report comparing the models are available at http://cisnet.
cancer.gov/prostate/profiles.html (AccessedMay 3, 2012).
The Fred Hutchinson Cancer Research
Center Model
In the Fred Hutchinson Cancer Research Center
(FHCRC) model, the risk of disease onset and associated
Gleason grade category, which is fixed at onset, depend on
age. Disease progresses from localized to metastatic stages
and from latent to symptomatic states based on risks that
depend on grade-specific PSA levels. Distributions of PSA
growth rates were estimated using longitudinal PSA meas-
urements from men in the control arm of the Prostate
Cancer Prevention Trial.9 Given individual PSA trajecto-
ries and natural histories; PSA screening patterns10; biopsy
compliance frequencies observed in the US-based Prostate,
Lung, Colorectal, and Ovarian cancer screening trial11,12;
and trends in biopsy sensitivity in the population,13 risks
of transitioning from 1 state to the next were estimated
using maximum likelihood to obtain parameter estimates
that best reproduce SEER incidence.14
The Erasmus University Medical Center
Microsimulation Screening Analysis Model
In the Erasmus University Medical Center MIcrosimula-
tion SCreening ANalysis (MISCAN) prostate model, can-
cer development is modeled as a semi-Markov process
governing transitions from 1 state to the next. In addition
to the healthy state, there are 18 states in the natural
history of prostate cancer that are derived from combina-
tions of clinical tumor (T1, T2, and T3) and metastasis
(M0 and M1) stages in the TNM staging system and
Gleason grade (well, moderately, and poorly differenti-
ated). Cancers in each state may be clinically diagnosed or
detected by a PSA test and subsequent biopsy, the proba-
bility of which is combined in a single sensitivity para-
meter that is state-specific. Model parameters (progression
rates between states and test sensitivities) were estimated
using data from the Rotterdam section of the ERSPC.15,16
For calibration to the US situation, we re-estimated the
test sensitivity parameters and estimated an additional
stage-specific risk of clinical diagnosis to capture different
pre-PSA disease diagnosis patterns in the United States
compared with Europe. US-specific estimates for the
parameters were obtained by calibrating the model to the
observed age-specific incidence and age-specific metastatic
stage distribution using maximum likelihood.17
The University of Michigan Model
The University of Michigan (UMICH) natural history
model consists of disease-free, preclinical, and clinical
states. An analytic formulation first estimates age-specific
and year-specific disease incidence based on PSA screen-
ing patterns,10 assuming parametric distributions for age
at onset and for time from onset to diagnosis, and increas-
ing test sensitivity with time since onset. Like the MIS-
CAN model, test sensitivity reflects both the diagnostic
properties of the test itself and the frequency and sensitiv-
ity of any subsequent biopsy. Parameters are estimated by
averaging over these distributions and calibrating the
resulting marginal incidence against observed incidence.18
Next, disease stage (SEER locoregional or distant) and
grade category (Gleason score 2-7 or 8-10) at diagnosis
are estimated based on time from onset to diagnosis and
mode of detection (screen or clinical) using a multinomial
logistic model.19 Maximum-likelihood estimation of the
joint model of age-specific incidence trends and stage/
grade distributions informs the distributions of these clin-
ical characteristics.
Modeling Survival
In the absence of treatment, all 3 models generate disease-
specific survival based on SEER data among men diag-
nosed just before the PSA era, during the calendar interval
from 1983 to 1986. A Poisson regression model is fit to
the disease-specific survival frequencies, censoring deaths
from other causes and adjusting for age, stage, and grade at
diagnosis and initial treatment (RP, RT, both, or neither).
Then, the fitted survival curve for men receiving neither
treatment is used to predict disease-specific survival times
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under no screening and no initial therapy. Relative to
locoregional survival, trends in survival for distant-stage
disease have remained fairly constant over time.20
Treatment Dissemination and Efficacy
Dissemination of treatment is modeled based on 2 data
sources. Trends in primary treatments—RP and RT—are
based on data from SEER, which records the first cancer-
directed therapy received. Trends in receipt of adjuvant or
neoadjuvant androgen-deprivation therapy (ADT), also
called hormone therapy, are based on the Cancer of the
Prostate Strategic Urologic Research Endeavor (CaP-
SURE) database.3,21 CaPSURE was initiated in 1995 to
document community trends in prostate cancer practice
patterns, epidemiology, and outcomes. It is a longitudinal,
observational database accruing data from 40 urologic prac-
tice sites over its history. Currently, there are over 14,000
men enrolled in CaPSURE. CaPSURE collects approxi-
mately 1000 clinical and patient-reported variables. Clini-
cal information is collected by the treating urologist at
baseline and with each follow-up visit. Figure 1 documents
trends in primary treatment by Gleason category.
We model 5 initial treatment courses for locore-
gional disease: CM, RP, RPþADT, RT, and RTþADT.
These treatments are modeled because they represent the
predominant treatment interventions used to treat pros-
tate cancer, because their use has changed over time, and
because there is quantitative evidence regarding efficacy
available from randomized trials. We grouped 3-dimen-
sional, conformal-beam, external-beam RT; intensity
modulated RT; and low-dose and high-dose interstitial
brachytherapy into a single RT. This was based on a
recent comparative effectiveness review from the Agency
for Healthcare Research and Quality’s Evidence-Based
Practice Center at Tufts University, which identified no
studies that reported a significant difference in overall sur-
vival or biochemical failure among the various forms of
radiation.22 Unfortunately, there are no randomized com-
parisons of all treatments; consequently, we integrate evi-
dence from several sources.
To briefly summarize the comparative effectiveness
results for these treatments, there is evidence that RP is
more efficacious than CM with a relative risk of 0.62.2 To
our knowledge, there are no clinical trials directly compar-
ing RP with RT; however, comparative effectiveness stud-
ies adjusting for case mix and progression risk consistently
demonstrate a benefit for RP over RT, with 2 recent stud-
ies producing adjusted relative risks of 0.45 and 0.47 for
the endpoint of disease-specific mortality.23,24 There is
evidence from clinical trials that RTþADT is more effica-
cious than RT alone25-27 and evidence from a recent com-
parative effectiveness study that RTþADT is similar to
RP (relative risk, 1.14 for RTþADT relative to RP; P ¼
.6124). For a recent review, seeWilt et al.28
On the basis of those studies, we assume a hazard
ratio of 0.62 for RP relative to CM and for RPþADT rel-
ative to CM, and we apply this to prostate cancer-specific
survival for untreated cases. However, to make the relative
benefit of RT alone consistent with published studies
either would require RT alone to be almost without
benefit or would require RTþADT to be far superior to
RP. Therefore, our assumed benefit range for RT com-
promises, reflecting lower benefit than either RP or
RTþADT, but not so low that it makes RT completely
ineffective. We also assume a time-varying relative risk
associated with RT relative to CM to reflect the improve-
ment in the efficacy of RT as more intense dose-delivery
regimens evolved. Specifically, we assume the hazard ratio
for RT relative to CM improved linearly from 0.9 in 1990
to 0.7 or 0.8 in 1995 and remained constant thereafter.
This assumption implies a relative risk for RP versus
RT that is either 0.62/0.8¼ 0.77 or 0.62/0.7¼ 0.89 after
1995. To reflect an even greater relative benefit of RP
relative to RT alone, consistent with recent comparative
effectiveness studies,23,24 we also conduct a high-efficacy
sensitivity experiment in which we use the more effica-
cious assumption for RT (hazard ratio, 0.7 relative to CM
after 1995) and lower the hazard ratio for RP relative to
CM to 0.4, suggesting a relative risk for RP versus RT of
0.4/0.7¼ 0.57 after 1995.
We also consider age-specific hazard ratios for all cu-
rative treatments based on the finding from the Scandina-
vian trial that RP was more beneficial in younger men
than in older men. Specifically, we consider hazard ratios
for RP, RPþADT, and RTþADT relative to CM of 0.49
for men ages 50 to 64 years at diagnosis and 0.83 for men
ages 65 to 84 years at diagnosis.2 Corresponding hazard
ratios for RT among men ages 50 to 64 years at diagnosis
improve from 0.9 in 1990 to 0.49  0.70/0.62  0.55
and to 0.49 0.80/0.62 0.63 in 1995, remaining con-
stant thereafter; whereas the hazard ratio for RT is con-
stant at 0.9 for men ages 65 to 84 years at diagnosis for all
years. In other words, we preserve the benefits of RT rela-
tive to RP within each age group. These 4 basic assump-
tion sets (not including the high-efficacy sensitivity
experiment) are summarized in Table 1.
Finally, we consider 2 additional sensitivity experi-
ments, both using the more efficacious assumptions for RP
(hazard ratio, 0.62 relative to CM for all ages) and RT (haz-
ard ratio, 0.7 relative to CM after 1995). The first uses the
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UMICH model and allows prostate cancer incidence to
continue its pre-PSA increase in the absence of screening,
lowering the both distant-stage incidence and prostate can-
cer mortality. The second uses the FHCRC model and
assumes that all patients who reportedly received CM in
SEER actually received RT as an extreme correction for
possible under-reporting of RT in SEER registries.29
RESULTS
Age-adjusted prostate cancer incidence trends observed in
the SEER registries are illustrated by stage in Figure 2.
Also illustrated are corresponding incidence trends pro-
jected by the 3 models. The model projections replicate
key features of the trends in locoregional incidence,
including the rapid escalation in the late 1980s, the peak
and initial decline in the early 1990s, and the stabilization
at a higher level in the late 1990s. There is greater variabil-
ity across models in the distant-stage trends, although all
models reproduce the scale of pre-PSA incidence and the
rapid decline in the middle to late 1990s.
We present incidence projections in the presence of
PSA screening to demonstrate how well the calibrated nat-
ural history models perform relative to observed inci-
dence. On the basis of these calibrated natural history
Table 1. Assumed Hazard Ratios for Prostate Cancer Survival for Primary and Hormone Treatments


















Assumption set 1 0.62 0.62 0.70 0.70
Assumption set 2 0.62 0.62 0.80 0.80
Assumption set 3 0.49 0.83 0.55 0.90
Assumption set 4 0.49 0.83 0.63 0.90
Abbreviations: ADT, androgen-deprivation therapy; RP, radical prostatectomy; RT, radiation therapy.
a All-age and age-specific hazard ratios for RP, RPþADT, and RTþADT are from Bill-Axelson et al2 with similarity between
RP and RTþADT based on Cooperberg et al.23 We assume RPþRT is similar to RP. The all-age hazard ratio for RT is
0.90 until 1990, improves linearly to 0.70 (assumption set 1) or 0.80 (assumption set 2) in 1995, and remains constant
thereafter. The age-specific hazard ratio for RT among men ages 50 to 64 yeas at diagnosis is 0.90 until 1990, improves
linearly to 0.55 (assumption set 3) or 0.63 (assumption set 4) in 1995, and remains constant thereafter; the hazard ratio
for RT among men ages 65 to 84 y at diagnosis is a constant 0.90 across calendar years.
Figure 2. Age-adjusted Surveillance, Epidemiology, and End Results (SEER) (black lines) and Cancer Intervention and Surveil-
lance Modeling Network (CISNET) model-projected prostate cancer incidence is illustrated in the presence (solid gray lines) and
absence (dashed gray lines) of prostate-specific antigen (PSA) screening. FHCRC indicates Fred Hutchinson Cancer Research
Center model; MISCAN, Erasmus University Medical Center Microsimulation Screening Analysis prostate model; UMICH, University
of Michigan model.
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models, under common assumptions about treatment and
survival, we project prostate cancer mortality in the ab-
sence of PSA screening.
Age-adjusted mortality projections that allow
benefit for each treatment based on assumption set 1 are
presented in Figure 3. All models reproduce the accumu-
lation of prostate cancer deaths by 1985 and slightly
underestimate the peak in 1991. All models project a
more-or-less constant continuation of mortality in the
absence of treatment benefit and a modest decrease in the
presence of treatment benefit. By 2005, mortality projec-
tions that allow benefit for all treatments represent up to
66% of the difference between mortality projected in the
absence of treatment benefit and observed mortality.
Table 2 provides a quantitative summary of the esti-
mated contribution of each treatment to the observed
mortality decline. The 3 models generally agree that
changes in RP and RT each played a role in the mortality
decline. Under assumption set 1, RP explains 11% to
14%, RT explains 9% to 16%, and ADT explains 1% to
3% of the mortality decline relative to projected mortality
in the absence of treatment benefit. Impacts are smaller
when treatment is less beneficial for older men; under
assumption set 4, corresponding impacts are 10% to
12%, 5% to 7%, and 1% to 3% (changes in treatment
explain 22%-33% to 16%-23% across the 4 sets of
assumed efficacy levels).
Despite conceptual differences across models about
how prostate cancer develops and progresses, the models
provide consistent results concerning the contributions of
treatment to the difference between observed mortality in
the year 2005 and the mortality that would have been
expected in the absence of advances in treatment. Specifi-
cally, the models project that prostate cancer mortality
would have stabilized at just under 100 deaths per
100,000 men ages 50 to 84 years in the absence of treat-
ment benefit. Our computation of the percentage of the
mortality decline explained by treatment trends in the
year 2005 indicates a significant role for primary treat-
ment, with treatment alone explaining up to 33% of the
difference between the observed mortality rate in the year
2005 and the rate projected in the absence of treatment
benefit.
Under our high-efficacy sensitivity experiment,
changes in treatment still explained only about half (range
across the 3 models, 42%-53%) of the decline in mortality
by 2005. Allowing prostate cancer incidence to continue
its pre-PSA increase in the absence of screening, the
UMICH model projects that changes in treatment
explained 30% rather than 22% of the decline in
Figure 3. Age-adjusted Surveillance, Epidemiology, and End Results (SEER) (black lines) and Cancer Intervention and Surveil-
lance Modeling Network (CISNET) (gray lines) model-projected prostate cancer mortality is illustrated for cases diagnosed after
January 1, 1975, under assumptions of no primary treatment benefit or a combination of primary treatments. Model projections
are based on assumption set 1 (see Table 1). For comparison, this figure also illustrates SEER prostate cancer mortality among all
cases. FHCRC indicates Fred Hutchinson Cancer Research Center model; MISCAN, Erasmus University Medical Center MIcrosimu-
lation SCreening ANalysis prostate model; UMICH, University of Michigan model; RP, radical prostatectomy; RT, radiation therapy;
ADT, androgen-deprivation therapy.
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mortality by 2005. And, assuming that all patients
reported as receiving CM in SEER actually received RT,
the FHCRC model projects that changes in treatment
explained 46% rather than 33% of the decline in mortal-
ity by 2005.
Thus, we conclude that advances in primary treat-
ment likely played an important role in the dramatic drop
in prostate cancer mortality observed since the early
1990s. However, changes in primary treatment alone do
not explain the majority of the mortality decline.
DISCUSSION
The decline in prostate cancer mortality that began in the
early 1990s has been striking and sustained. Between
1994 and 2005, prostate cancer deaths dropped by an av-
erage rate of 4.1% per year, and they are still declining. In
the current study, we used comparative modeling to inves-
tigate 1 of the most plausible explanations for the mortal-
ity decline, ie, changes in primary treatment, with the
objective of also shedding light on the potential roles of
screening and other interventions. Our results indicate
that treatment explains a nontrivial fraction of the drop in
disease-specific deaths, but the majority of the decline is
likely explained by other factors, such as screening or
improvements in disease management after primary ther-
apy. For example, with almost all patients being moni-
tored with PSA after diagnosis, metastatic or potentially
metastatic tumors are being retreated considerably
earlier.30 Salvage treatments received at the time of bio-
chemical failure have been associated with signifi-
cant improvements in disease-specific survival.31 These
changes in secondary disease management may have been
primarily responsible for the early decline in mortality;
based on recent screening trial results, we would not
expect to observe a substantial decline in mortality as early
as was observed because of screening alone.
Our results rest on several key assumptions. First,
each natural history model makes different assumptions
about disease onset, progression, and diagnosis in the ab-
sence of screening. Consequently, the 3 models project 3
estimates for the fraction of the mortality decline
explained by treatment. We observe that our conclusions
are robust even given this intermodel uncertainty. Second,
all models assume that disease incidence would have
remained constant at pre-PSA levels after 1987. A sensitiv-
ity experiment indicated that our conclusions are robust
even if disease incidence would have continued its increas-
ing trend. Third, all models assume that baseline (in the
absence of screening or treatment) prostate cancer survival
remained constant in the PSA era. Even if this survival
improved over time, perhaps because of advances in treat-
ing recurrent disease, this would have little impact on our
results, because it would suggest similar relative differen-
ces between projected mortality rates in the presence and
absence of changes in treatment.
Our study uses data from a variety of sources
that are subject to limitations. Although SEER is the
most authoritative resource for information on disease
Table 2. Projected Prostate Cancer Mortality Rates per 100,000 Men Ages 50 to 84 Years in 2005 by Model, Assumption About
Primary and Hormone Treatment Benefit, and Treatment Allowing Benefita
Model None RP RT RT1ADT RP1RT RP1RT1ADT
FHCRC
Set 1 95.8 90.6 (14.4) 90 (16.2) 88.9 (19) 84.8 (30.5) 83.8 (33.4)
Set 2 95.8 90.6 (14.4) 91.9 (10.7) 89.5 (17.4) 86.8 (25.1) 84.4 (31.8)
Set 3 95.8 91.3 (12.4) 92.8 (8.2) 91.8 (10.9) 88.4 (20.7) 87.4 (23.4)
Set 4 95.8 91.3 (12.4) 93.1 (7.4) 92 (10.5) 88.7 (19.8) 87.5 (23)
MISCAN
Set 1 97.1 92 (13.7) 90.9 (16.6) 90.5 (17.7) 85.8 (30.3) 85.4 (31.3)
Set 2 97.1 92 (13.7) 93.0 (10.9) 91.5 (15) 88 (24.6) 86.4 (28.7)
Set 3 97.1 94.4 (7.3) 94.2 (7.8) 93.8 (8.8) 91.5 (15.1) 91.1 (16.2)
Set 4 97.1 94.4 (7.3) 94.4 (7.3) 93.9 (8.7) 91.6 (14.7) 91.1 (16)
UMICH
Set 1 98 93.8 (10.8) 94.5 (9.1) 93.8 (10.9) 90.4 (20) 89.7 (21.6)
Set 2 98 93.8 (10.8) 95.6 (6.3) 94.3 (9.6) 91.5 (17) 90.1 (20.6)
Set 3 98 94.1 (10.1) 95.9 (5.3) 95.4 (6.8) 92 (15.6) 91.5 (16.9)
Set 4 98 94.1 (10.1) 96.1 (4.9) 95.4 (6.7) 92.2 (15.1) 91.6 (16.7)
Abbreviations: ADT, androgen-deprivation therapy; FHCRC, Fred Hutchinson Cancer Research Center model; MISCAN, Erasmus University Medical Center
Microsimulation Screening Analysis prostate model; RP, radical prostatectomy; RT, radiation therapy; UMICH, University of Michigan model.
a The corresponding mortality rate from Surveillance, Epidemiology, and End Results (SEER) was 59.9 in 2005. Percentage declines relative to the difference
between mortality projected for no treatment benefit and SEER observed mortality are indicated in parentheses.
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incidence and survival in the United States, we note again
that estimates of prostate cancer survival in the absence of
screening are not available in the PSA era. We also use
SEER data on the first course of cancer-directed therapy
to estimate the frequencies of RP and RT. A sensitivity
experiment indicated that our conclusions are robust even
if all patients recorded as receiving CM in SEER actually
received RT. Finally, our treatment efficacy estimates,
which are based on the most rigorous and up-to-date
results from randomized trials and comparative effective-
ness studies, still are subject to moderate uncertainty. Our
sensitivity experiments demonstrated that our conclusions
are robust even assuming that RP primarily benefits
younger men and/or assuming that improvements in radi-
ation technology achieved efficacy similar to RP.
The models use estimates of the efficacy of RP rela-
tive to CM from the benchmark Scandinavian random-
ized controlled trial.2 A recent observational study32
compared Medicare patients in the United States who did
and did not undergo RP. After adjusting for selection,
those authors observed an advantage for surgery, even
among older men, who did not benefit significantly in the
Scandinavian trial. If surgery is more efficacious in the
United States, then our results may be somewhat conserv-
ative, because changes in the frequency of RP are associ-
ated with an important portion of the decline in mortality
associated with primary treatment.
In conclusion, the results of this modeling study
clearly identify a role for primary treatment changes in US
prostate cancer mortality declines, but a large fraction of the
decline is left unexplained. This clearly suggests a role for
PSA screening, but it also indicates that we should not
assume that screening is as effective as suggested by the over-
all drop in prostate cancer mortality observed in the PSA
era. Indeed, there is a clear role for primary treatment
change and possibly advances in treatment for recurrent or
progressive disease, and there may be a synergy with earlier
detection because of screening. Further modeling studies
will investigate the extent to which screening and treat-
ments jointly explain the mortality decline and will also
highlight the role of other interventions, such as advances in
disease management for recurrent andmetastatic disease.
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